Emerging drugs for irritable bowel syndrome
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Irritable bowel syndrome (IBS) is one of the most common chronic gastrointestinal disorders, yet its pathophysiology is incompletely understood and pharmacological treatments remain unsatisfactory. Current therapeutic choices include a range of drugs aimed at normalising bowel habits, reducing pain or treating comorbid psychological symptoms. However, this individual symptom-targeted approach remains unsatisfactory in terms of global symptom relief and patient satisfaction. In the last decade, further characterisation of IBS pathophysiology has provided new and exciting targets at different levels of the brain-gut axis for the development of several candidate drugs. Advances in clinical trial design will help to evaluate these compounds in different IBS patient populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barbara, G., Stanghellini, V., De Giorgio, R., Cremon, C., Cottrell, G. S., Santini, D., Pasquinelli, G., Morselli-Labate, A. M., Grady, E. F., Bunnett, N. W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.055 · Cited by 1,475 · cited 2×
“Recent findings from Barbara and colleagues reported evidence for a close proximity of tryptase-positive mast cells and nerves, along with correlation of these intimate nerve to mast cell interactions with severity of abdominal pain in IBS patients [70-71].”
BackgroundO’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448 · cited 1×
“In contrast, a recent study [166] comparing the response of symptoms and cytokine ratio in IBS patients with ingestion of probiotic preparations containing L.”
ResultAGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
Self-citationDiatchenko, L., Slade, G. D., Nackley, A. G., Bhalang, K., Sigurdsson, A., Belfer, I., Goldman, D., Xu, K., Shabalina, S. A., Shagin, D., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi013 · Cited by 1,280 · cited 1×
“The hypothesised role of the noradrenergic system in the pathophysiology of IBS [2] has been supported by recent findings showing the association of functional α2-adrenoreceptor polymorphisms with constipation and high somatic symptoms in patients with lower functional bowel disorders [150], as well as in other functi…”
ResultSpiller, R. C., Jenkins, D., Thornley, J. P., Hebden, J. M., Wright, T., Skinner, M., & Neal, K. R. (2000) · Gut · doi:10.1136/gut.47.6.804 · Cited by 1,155 · cited 2×
“For example, a small increase in the number of 5-HT-containing cells in the colonic mucosa of postinfectious IBS patients has been described by several groups [44-45].”
BackgroundActivation of the mucosal immune system in irritable bowel syndrome
Chadwick, V. S., Chen, W., Shu, D., Paulus, B., Bethwaite, P., Tie, A., & Wilson, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.33579 · Cited by 833 · cited 2×
“All IBS patients that were studied exhibited elevated intestinal intraepithelial lymphocytes, CD3+ and CD25+ cells in the lamina propria [16].”
BackgroundEradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780 · cited 2×
“2 Antibiotics The rationale for the use of antibiotics in the treatment of IBS emanates from the observation that small bowel bacterial overgrowth may be present in a significant number of patients who meet diagnostic criteria for IBS [80].”
BackgroundDrossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., Emmott, S., Proffitt, V., Akman, D., Frusciante, K., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00669-3 · Cited by 614 · cited 1×
“In a recent large randomised 12-week placebo-controlled trial [33], including 431 female adult patients, Drossman et al.”
BackgroundDunlop, S. P., Jenkins, D., Neal, K. R., & Spiller, R. C. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.028 · Cited by 583
Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial
Atkinson, W., Sheldon, T. A., Shaath, N., & Whorwell, P. J. (2004) · Gut · doi:10.1136/gut.2003.037697 · Cited by 534 · cited 1×
“In this study, foods most likely to be associated with IgG antibodies were wheat, milk, yeast, eggs and cashew nuts [23].”
BackgroundTörnblom, H., Lindberg, G., Nyberg, B., & Veress, B. (2002) · Gastroenterology · doi:10.1053/gast.2002.37059 · Cited by 516 · cited 2×
“Preliminary evidence for such an immune-based hypothesis comes from several different lines of investigation in IBS patients, as well as preclinical observations [67-74].”
BackgroundIrritable bowel syndrome in the United States: prevalence, symptom patterns and impact
Hungin, A. P. S., Chang, L., Locke, G. R., Dennis, E. H., & Barghout, V. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02463.x · Cited by 494 · cited 1×
“More than half of IBS patients seeking medical care are prescribed some form of medication, and about the same number are provided with dietary and lifestyle recommendations [5].”
BackgroundIncreased mast cells in the irritable bowel syndrome
O’Sullivan, Clayton, Breslin, Harman, Bountra, Mclaren, & O’Morain (2000) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2000.00221.x · Cited by 480 · cited 2×
“Preliminary evidence for such an immune-based hypothesis comes from several different lines of investigation in IBS patients, as well as preclinical observations [67-74].”
BackgroundArnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471 · cited 1×
“Another SNRI compound, duloxetine, has recently been demonstrated to reduce pain in another chronic functional pain syndrome, fibromyalgia, which is frequently associated with IBS [118].”
BackgroundThe cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome
Creed, F., Fernandes, L., Guthrie, E., Palmer, S., Ratcliffe, J., Read, N., Rigby, C., Thompson, D., & Tomenson, B. (2003) · Gastroenterology · doi:10.1053/gast.2003.50055 · Cited by 443
Gwee, K.-A. (2003) · Gut · doi:10.1136/gut.52.4.523 · Cited by 415 · cited 2×
“In addition, increased expression of IL-1β mRNA in PI-IBS patients was observed in rectal and ileum biopsies in two independent studies [76-77], thus providing supporting evidence for an immune-activation component in PI-IBS patients expressing IBS-like symptoms.”
BackgroundResultV. Stress and irritable bowel syndrome
Mayer, E. A., Naliboff, B. D., Chang, L., & Coutinho, S. V. (2001) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2001.280.4.g519 · Cited by 413
Self-citationPrather, C. M., Camilleri, M., Zinsmeister, A. R., McKinzie, S., & Thomforde, G. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70251-4 · Cited by 410 · cited 1×
“For example, tegaserod accelerates upper and lower gut transit in healthy subjects [104], promotes gastric emptying, small bowel and colonic transit in IBS-C patients [52] and increases fecal water and intestinal secretion in female subjects [105].”
BackgroundSanders, D. S., Carter, M. J., Hurlstone, D. P., Pearce, A., Ward, A. M., McAlindon, M. E., & Lobo, A. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06581-3 · Cited by 390
Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis
Wang, L.-H., Fang, X.-C., & Pan, G.-Z. (2004) · Gut · doi:10.1136/gut.2003.021154 · Cited by 387 · cited 1×
“In addition, increased expression of IL-1β mRNA in PI-IBS patients was observed in rectal and ileum biopsies in two independent studies [76-77], thus providing supporting evidence for an immune-activation component in PI-IBS patients expressing IBS-like symptoms.”
ResultTerminal ileal mucosal mast cells in irritable bowel syndrome
Weston, A. P., Biddle, W. L., Bhatia, P. S., & Miner, P. B. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303164 · Cited by 338 · cited 2×
“Preliminary evidence for such an immune-based hypothesis comes from several different lines of investigation in IBS patients, as well as preclinical observations [67-74].”
BackgroundThe Irritable Bowel Syndrome: Review and a Graduated Multicomponent Treatment Approach
Drossman, D. A., & Thompson, W. G. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-12-1009 · Cited by 309 · cited 1×
“Whereas education, reassurance and recommendations on lifestyle changes (aimed largely at reducing symptom-related anxiety and increasing self efficacy) may be sufficient for symptom relief in patients with mild symptoms [18-20], a multidisciplinary approach combining pharmacotherapy and”
BackgroundSagami, Y., Shimada, Y., Tayama, J., Nomura, T., Satake, M., Endo, Y., Shoji, T., Karahashi, K., Hongo, M., & Fukudo, S. (2004) · Gut · doi:10.1136/gut.2003.018911 · Cited by 291 · cited 1×
“reported an inhibitory effect of intravenous injection of the non-CNS penetrable CRF receptor antagonist, α-helical CRF9–41, on exaggerated motility induced by colonic distension and electrical stimulation of the rectal mucosa in IBS-D patients [149].”
BackgroundEffect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
Delvaux, M., Louvel, D., Mamet, J. ‐., Campos‐Oriola, R., & Frexinos, J. (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00375.x · Cited by 236
NIV, E., NAFTALI, T., HALLAK, R., & VAISMAN, N. (2005) · Clinical Nutrition · doi:10.1016/j.clnu.2005.06.001 · Cited by 191
The economic impact of irritable bowel syndrome
Inadomi, J. M., Fennerty, M. B., & Bjorkman, D. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.t01-1-01736.x · Cited by 190 · cited 1×
“7 and $10 billion in direct medical cost (repetitive use of multiple healthcare resources) and $20 billion for indirect costs (work absenteeism and impaired productivity), representing a high socioeconomic burden on society [8].”
BackgroundRaybould, H. E., Glatzle, J., Robin, C., Meyer, J. H., Phan, T., Wong, H., & Sternini, C. (2003) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00292.2001 · Cited by 164 · cited 1×
“1 5-HT3 receptor antagonists 5-HT3Rs are expressed on subsets of neurons intrinsic to the enteric nervous system (intrinsic primary afferent neurons; IPANs) as well as on extrinsic primary afferents (both spinal and vagal afferents) [47-48].”
BackgroundCondition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron
Berman, S. M., Chang, L., Suyenobu, B., Derbyshire, S. W., Stains, J., FitzGerald, L., Mandelkern, M., Hamm, L., Vogt, B., Naliboff, B. D., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35990 · Cited by 139
Self-citationHoughton, Foster, & Whorwell (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00762.x · Cited by 132 · cited 1×
“Initial studies in human subjects have demonstrated that the 5-HT3R antagonist alosetron slows intestinal transit in both IBS patients (patients with severe constipation were excluded) and healthy controls [91].”
BackgroundAntidepressants for irritable bowel syndrome: Figure 1
Clouse, R. E. (2003) · Gut · doi:10.1136/gut.52.4.598 · Cited by 74
Pimentel, M. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.06057.x · Cited by 6
Cited by
Enck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Niesler, B., Quigley, E. M. M., Rajilić-Stojanović, M., Schemann, M., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.14 · Cited by 997
Self-citationThe brain-gut axis in abdominal pain syndromes.
Mayer, E. A., & Tillisch, K. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-012309-103958 · Cited by 511
Self-citationMayer, E. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0801447 · Cited by 243
Self-citationLackner, J. M., Jaccard, J., Krasner, S. S., Katz, L. A., Gudleski, G. D., & Blanchard, E. B. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.014 · Cited by 172
Tillisch, K., Labus, J., Nam, B., Bueller, J., Smith, S., Suyenobu, B., Siffert, J., McKelvy, J., Naliboff, B., & Mayer, E. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04958.x · Cited by 60
Self-citation
Metadata
- Authors
- Bradesi, S., Tillisch, K., & Mayer, E.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2006-04-24
- Volume
- 11
- Issue
- 2
- Pages
- 293-313
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2101443744
- Cited by
- 14
- References
- 31
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.